D-1249-2019 Class II Ongoing

Recalled by AVKARE Inc. — Pulaski, TN

FDA drug recall D-1249-2019 was initiated by AVKARE Inc. on Apr 24, 2019 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million. The recall status is ongoing. Affected quantity: 1438 cartons (71,900 tablets).

Recall details

Product Type
Drugs
Report Date
May 8, 2019
Initiation Date
Apr 24, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1438 cartons (71,900 tablets)

Product description

Losartan Potassium Tablets USP 50 mg 50 tablets (5x10) Unit Dose Rx Only NDC 50268-517-15 Manufactured for: AvKARE Inc. Pulaski, TN 38478

Reason for recall

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.

Distribution pattern

Nationwide

Code information

Lot: 20121 Exp. 6/30/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1249-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1249-2019. Report a data issue: hello@regdatalab.com.